Maxigen Biotech Inc. (1783) AI Stock Analysis

Maxigen Biotech Inc.

(TWSE:1783)

Select Model

Rating:75Outperform

Price Target:TWD 39.00▲(8.33% Upside)

Action:initiatedcoverage

Date:11/09/26

Strong financial performance and attractive valuation are the primary drivers of the score, partially offset by weak technical momentum.

Positive Factors

Strong ProfitabilityHigh and improving margins indicate substantial earnings power in the current business model. Compared with 2020, stronger gross, operating, and net margins provide more internal funding for development and commercialization while offering resilience if revenue growth moderates.

Negative Factors

Revenue Surge RepeatabilityThe exceptional 2025 revenue increase creates execution risk because such a large step-up may not recur at the same pace. If demand or recognition effects were temporary, future growth could normalize sharply, making earnings expectations and resource planning less predictable.

Maxigen Biotech Inc. (1783) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 3.23B
Dividend Yield: 5.55%
Average Volume (3M): 73.17K
Price to Earnings (P/E): 9.4
Beta (1Y): 0.30
Revenue Growth: 8.14%
EPS Growth: 29.10%
Country: TW
Employees: 127
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Maxigen Biotech Inc. Business Overview & Revenue Model

Company Description

Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Fo...

Maxigen Biotech Inc. Financial Statement Overview

Summary

Strong financial profile with steady revenue growth to 812 million, high gross margins of 69.5%, net margins of 32.7%, minimal debt-to-equity of 0.07, and solid operating cash flow of 290 million.

Income Statement

87Very Positive

Balance Sheet

93Very Positive

Cash Flow

80Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	837.44M	811.56M	680.65M	622.12M	604.43M	511.98M
Gross Profit	585.43M	563.72M	483.32M	424.09M	373.99M	261.03M
EBITDA	304.68M	293.18M	221.40M	177.09M	195.43M	130.56M
Net Income	291.20M	265.31M	190.17M	165.83M	139.40M	87.67M
Balance Sheet
Total Assets	2.03B	1.89B	1.58B	1.49B	1.45B	1.27B
Cash, Cash Equivalents and Short-Term Investments	997.26M	877.69M	640.55M	432.58M	801.26M	540.18M
Total Debt	102.25M	101.40M	0	50.00K	0	9.74M
Total Liabilities	534.02M	355.54M	207.36M	131.88M	152.07M	123.47M
Stockholders Equity	1.50B	1.54B	1.38B	1.36B	1.30B	1.14B
Cash Flow
Free Cash Flow	241.33M	207.59M	266.45M	148.76M	253.90M	102.15M
Operating Cash Flow	332.49M	290.22M	298.22M	171.20M	268.34M	117.59M
Investing Cash Flow	-338.04M	-382.99M	-29.07M	-490.25M	10.43M	-2.77M
Financing Cash Flow	24.82M	30.66M	-59.73M	-41.39M	-1.05M	188.69M

Maxigen Biotech Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1783 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1783	75Outperform	TWD 3.16B	9.38	―	5.55%	8.14%	29.10%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6733	46Neutral	TWD 2.80B	-31.69	―	―	10.74%	21.61%
TW:6461	42Neutral	TWD 2.94B	-5.62	―	―	-57.87%	-21.67%
TW:6875	37Underperform	TWD 3.24B	-9.23	―	―	-69.26%	-24.53%

* General Sector Average

Performance Comparison

TW:1783 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1783	Maxigen Biotech Inc.	36.00	-6.25	-14.80%
TW:4178	Stemcyte International Ltd.	15.50	-7.95	-33.90%
TW:6461	Intech Biopharm Ltd	26.20	1.30	5.24%
TW:6733	BioGend Therapeutics Co., Ltd.	21.00	-17.88	-45.98%
TW:6875	Pharmosa Biopharm Inc.	25.25	-24.25	-48.99%
TW:7427	Great Novel Therapeutics Biotech & Medicals Corp.	59.00	18.63	46.16%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Maxigen Biotech Inc. AI Stock Analysis